Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of GC1109 Anthrax Vaccine in Healthy Adults
NCT01624532Phase 2Completed
- Sponsor
- GC Biopharma
- Start
- Jul 2021
- Primary completion
- Aug 2022
- Modality
- Viral Vector Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BARYTHRAX in anthrax (4 arms), sponsored by GC Biopharma. Primary endpoints: Optimum volume of GC1109 and Toxin Neutralization Antibody by TNA assay. Started Jul 2021; status: completed.
02
Drugs
BARYTHRAX
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT01624532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01624532.